ERBB2 and breast cancer: HER2 overexpression has an important prevalence, nearly to ~22% in breast cancer; the upregulation of HER2 is associated with different histological characteristics of the tumor, metastasis and invasiveness, angiogenesis, and a poor overall prognosis.24 Several miRNA have been associated with overexpression of HER2.25 Also, the genotype AG of rs584298 in TRIM62 shows association with expression of PR status, possibly the causal variant could be the SNP in the miRNA binding site rs689187 affecting the expression of PR.